Millions of Americans, including those on Medicare, are set to benefit as the Trump administration announces deals with Novo Nordisk and Eli Lilly to cut prices for GLP-1 drugs used to treat obesity and diabetes.
The agreements set negotiated prices for both the government and consumers, covering medications used for obesity, diabetes, and other cardiometabolic conditions.
Under the new public-private partnership “TrumpRx,” patients using injectable GLP-1 drugs will pay approximately $350 for a month’s supply, with prices expected to drop to $250 over the next two years for those paying entirely out-of-pocket.
GLP-1 drugs currently cost roughly $500 out-of-pocket for those without insurance. Daily pill versions of the drug, still awaiting FDA approval, will start at $150 for initial doses, with availability expected next year pending approval.
Speaking from the Oval Office, President Trump praised the agreements, saying, “This is a triumph for American patients that will save lives and improve the health of millions and millions of Americans”.
The deals also expand access for Medicare patients with severe obesity, who will have a $50 co-pay and could see new pricing as early as mid-2026. Medicaid pricing and rollout will vary by state depending on participation.
This initiative is part of the administration’s broader “most favored nations” strategy to reduce drug costs, following an executive order in May directing the pursuit of such agreements.
In a statement, the President and CEO of Novo Nordisk, Mike Doustdar, said the deal will increase patient access and affordability, reflecting the administration’s push to make critical medications more attainable for Americans.
About the Author
